Alicia Phillips, MD
Physical Medicine & Rehabilitation · Minneapolis, MNNPI 1053765628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 41.3% of the total. Reporting peaked in 2023 at $144 and has fallen 62.6% since, to $54 in 2025.
Across 10 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$106
- Merz Pharmaceuticals, LLC$66
- Ipsen Biopharmaceuticals, Inc$50
- Collegium Pharmaceutical, Inc.$18
- Si-bone, Inc.$16
What the payments were for
- Food & beverage$256100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $106 |
| Merz Pharmaceuticals, LLC | 2 | $66 |
| Ipsen Biopharmaceuticals, Inc | 2 | $50 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $16 |
How this compares
$256 in reported general payments places this provider in the 70th percentile of 196 physical medicine & rehabilitation providers in Minnesota.
See all physical medicine & rehabilitation providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,856 |
| Celecoxib | 70 | $1,168 |
| Diphenhydramine Hcl | 26 | $838 |
| Lactated RingersRinger's Solution,lactated | 20 | $604 |
| Meloxicam | 41 | $355 |
| Methocarbamol | 26 | $269 |
| RizatriptanRizatriptan Benzoate | 13 | $209 |
| Ondansetron HclOndansetron Hcl/Pf | 26 | $146 |
| Meperidine HclMeperidine Hcl/Pf | 18 | $117 |
| Diclofenac Sodium | 11 | $100 |
| Cyclobenzaprine Hcl | 18 | $88 |
| Diazepam | 11 | $7 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Minneapolis
- Sarah WinemanMinneapolis$20K
- Tyler ShirelMinneapolis$15K
- Ian AckersMinneapolis$8K
- Grant GustafsonMinneapolis$6K
- Parisa SalehiMinneapolis$1K
- Mahmood GharibMinneapolis$658
- Jennifer ThomasMinneapolis$325
- Marilyn WeberMinneapolis$286
- Sandra RosenbergMinneapolis$266
- Amanda DerasmiMinneapolis$261
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.